Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.63 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5770525 | 0.90 | PTPN1 (0.65) | PTPN1PTPN2OPRM1OPRK1OPRD1 | |
| SCHEMBL5771521 | 0.88 | PTPN1 (0.61) | PTPN1PTPN2OPRM1OPRK1OPRD1 | |
| SCHEMBL5769588 | 0.88 | PTPN1 (0.59) | PTPN1OPRM1OPRK1OPRD1 | |
| SCHEMBL5769105 | 0.87 | PTPN1 (0.59) | PTPN1PTPN2OPRM1OPRK1OPRD1 | |
| SCHEMBL5769077 | 0.87 | PTPN1 (0.59) | PTPN1PTPN2OPRM1OPRK1OPRD1 | |
| SCHEMBL5769028 | 0.85 | PTPN1 (0.58) | PTPN1PTPN2OPRM1OPRK1OPRD1 | |
| SCHEMBL5768763 | 0.85 | PTPN1 (0.56) | PTPN1PTPN2PTPRC | |
| SCHEMBL5769484 | 0.84 | PTPN1 (0.59) | PTPN1PTPN2OPRM1OPRK1OPRD1 | |
| SCHEMBL5767679 | 0.84 | PTPN1 (0.81) | PTPN1PTPN2 | |
| SCHEMBL5769149 | 0.84 | PTPN1 (0.81) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301516-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK AS (DK) | 2006-03-22 | — | — | EP | disclosed |
| US-6613903-B2 | Such as 7-(benzoylamino-methyl)-2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno(2,3 -c)pyridine-3-carboxylic acid for treatment of diabetes, insulin resistance, and obesity | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| EP-1301516-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2003-04-16 | — | — | EP | disclosed |
| US-20020151561-A1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151561-A1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | PTPRO, PTPN1, PTPRS | PTPN1 2/4885PTPN2 12/4885OPRM1 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.